Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".
Volume
5
Pagination
188le2 - ?
Publisher
DOI
10.1126/scitranslmed.3005065
Journal
Sci Transl Med
Issue
Metadata
Show full item recordAbstract
Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.